{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:56:17Z","timestamp":1776398177147,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00192-024-05791-7","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T13:01:34Z","timestamp":1714741294000},"page":"1375-1379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anticholinergic Burden in Patients Treated for Overactive Bladder: Second-Line Therapy with Tibial Nerve Stimulation as a Solution"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-2348","authenticated-orcid":false,"given":"Nihal","family":"Satyadev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Ameen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trieu H.","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"issue":"3","key":"5791_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/nau.22295","volume":"32","author":"KS Coyne","year":"2013","unstructured":"Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial\/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230\u20137. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/nau.22295","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"5791_CR2","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/nau.23477","volume":"37","author":"LC Powell","year":"2018","unstructured":"Powell LC, Szabo SM, Walker D, Gooch K. The economic burden of overactive bladder in the United States: a systematic literature review. Neurourol Urodyn. 2018;37(4):1241\u20139. https:\/\/doi.org\/10.1002\/nau.23477.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"5791_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J Urol. 2019;202(3):558\u201363. https:\/\/doi.org\/10.1097\/JU.0000000000000309.","journal-title":"J Urol"},{"issue":"12","key":"5791_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.7326\/0003-4819-156-12-201206190-00436","volume":"156","author":"T Shamliyan","year":"2012","unstructured":"Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156(12):861\u201374, W301\u201310. https:\/\/doi.org\/10.7326\/0003-4819-156-12-201206190-00436","journal-title":"Ann Intern Med"},{"issue":"4","key":"5791_CR5","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.juro.2009.12.036","volume":"183","author":"KM Peters","year":"2010","unstructured":"Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438\u201343. https:\/\/doi.org\/10.1016\/j.juro.2009.12.036.","journal-title":"J Urol"},{"issue":"5","key":"5791_CR6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.juro.2010.06.113","volume":"184","author":"E Finazzi-Agr\u00f2","year":"2010","unstructured":"Finazzi-Agr\u00f2 E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001\u20136. https:\/\/doi.org\/10.1016\/j.juro.2010.06.113.","journal-title":"J Urol"},{"issue":"8","key":"5791_CR7","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/nau.22251","volume":"31","author":"C Burton","year":"2012","unstructured":"Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206\u201316. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22251","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"5791_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/nau.23351","volume":"37","author":"J Booth","year":"2018","unstructured":"Booth J, Connelly L, Dickson S, Duncan F, Lawrence M. The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: a systematic review. Neurourol Urodyn. 2018;37(2):528\u201341. https:\/\/doi.org\/10.1002\/nau.23351.","journal-title":"Neurourol Urodyn"},{"issue":"45","key":"5791_CR9","doi-asserted-by":"publisher","first-page":"e27745","DOI":"10.1097\/MD.0000000000027745","volume":"100","author":"L Xia","year":"2021","unstructured":"Xia L, Yan H, Sun Y, et al. Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome. Medicine. 2021;100(45):e27745. https:\/\/doi.org\/10.1097\/MD.0000000000027745.","journal-title":"Medicine"},{"issue":"5","key":"5791_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","volume":"65","author":"CC Sexton","year":"2011","unstructured":"Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567\u201385. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02626.x.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"5791_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/nau.24254","volume":"39","author":"MJ Te Dorsthorst","year":"2020","unstructured":"Te Dorsthorst MJ, Heesakkers JPFA, van Balken MR. Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients. Neurourol Urodyn. 2020;39(2):702\u20136. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/nau.24254","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"5791_CR12","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.juro.2012.11.175","volume":"189","author":"KM Peters","year":"2013","unstructured":"Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194\u2013201. https:\/\/doi.org\/10.1016\/j.juro.2012.11.175.","journal-title":"J Urol"},{"key":"5791_CR13","first-page":"1","volume":"6","author":"J Jayarajan","year":"2014","unstructured":"Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2014;6:1\u201316. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3862648\/","journal-title":"Res Rep Urol"},{"issue":"12","key":"5791_CR14","doi-asserted-by":"publisher","first-page":"204209862110125","DOI":"10.1177\/20420986211012592","volume":"6","author":"M Herrero-Zazo","year":"2021","unstructured":"Herrero-Zazo M, Berry R, Bines E, Bhattacharya D, Myint PK, Keevil VL. Anticholinergic burden in older adult inpatients: patterns from admission to discharge and associations with hospital outcomes. Ther Adv Drug Saf. 2021;6(12):20420986211012590. https:\/\/doi.org\/10.1177\/20420986211012592.","journal-title":"Ther Adv Drug Saf"},{"issue":"361","key":"5791_CR15","doi-asserted-by":"publisher","first-page":"k1315","DOI":"10.1136\/bmj.k1315","volume":"25","author":"K Richardson","year":"2018","unstructured":"Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;25(361):k1315. https:\/\/doi.org\/10.1136\/bmj.k1315.","journal-title":"BMJ"},{"issue":"8","key":"5791_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084\u201393. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0677.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"5791_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ageing\/afaa090","volume":"49","author":"NT Pieper","year":"2020","unstructured":"Pieper NT, Grossi CM, Chan WY, Loke YK, Savva GM, Haroulis C, et al. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age Ageing. 2020;49(6):939\u201347. https:\/\/doi.org\/10.1093\/ageing\/afaa090.","journal-title":"Age Ageing"},{"issue":"1","key":"5791_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.juro.2012.08.085","volume":"189","author":"M Martinson","year":"2013","unstructured":"Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189(1):210\u20136. https:\/\/doi.org\/10.1016\/j.juro.2012.08.085.","journal-title":"J Urol"},{"issue":"7","key":"5791_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11934-020-00980-5","volume":"21","author":"A Vollstedt","year":"2020","unstructured":"Vollstedt A, Gilleran J. Update on implantable PTNS devices. Curr Urol Rep. 2020;21(7):28. https:\/\/doi.org\/10.1007\/s11934-020-00980-5.","journal-title":"Curr Urol Rep"},{"issue":"3","key":"5791_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324\u201333. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S030228381830201X","journal-title":"Eur Urol"},{"issue":"1","key":"5791_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","volume":"77","author":"CR Chapple","year":"2020","unstructured":"Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119\u201328. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.024.","journal-title":"Eur Urol"},{"issue":"12","key":"5791_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/13696998.2016.1204307","volume":"19","author":"RC Wielage","year":"2016","unstructured":"Wielage RC, Perk S, Campbell NL, et al. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare advantage perspectives. J Med Econ. 2016;19(12):1135\u201343. https:\/\/doi.org\/10.1080\/13696998.2016.1204307.","journal-title":"J Med Econ"},{"key":"5791_CR23","doi-asserted-by":"publisher","unstructured":"AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder. Female Pelvic Med Reconstr Surg. 2017;23(3):177\u20138. https:\/\/doi.org\/10.1097\/SPV.0000000000000423","DOI":"10.1097\/SPV.0000000000000423"},{"issue":"8","key":"5791_CR24","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/nau.25037","volume":"41","author":"J Zillioux","year":"2022","unstructured":"Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41(8):1928\u201333. https:\/\/doi.org\/10.1002\/nau.25037.","journal-title":"Neurourol Urodyn"},{"key":"5791_CR25","unstructured":"Centers for Medicare & Medicaid Services. Posterior Tibial Nerve Stimulation (PTNS). Centers for Medicare & Medicaid services: Medicare coverage database. 2019. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33406&ver=10"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-024-05791-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-024-05791-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-024-05791-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T23:02:55Z","timestamp":1729378975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-024-05791-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5791"],"URL":"https:\/\/doi.org\/10.1007\/s00192-024-05791-7","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"30 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a clinical opinion. No IRB was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}